KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) Shares Outstanding (Diluted Average) (2020 - 2025)

Medpace Holdings (MEDP) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $29.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) fell 7.77% year-over-year to $29.5 million, compared with a TTM value of $29.5 million through Dec 2025, down 7.77%, and an annual FY2025 reading of $29.5 million, down 7.77% over the prior year.
  • Shares Outstanding (Diluted Average) was $29.5 million for Q4 2025 at Medpace Holdings, up from $28.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $37.7 million in Q4 2021 and bottomed at $28.8 million in Q3 2025.
  • Average Shares Outstanding (Diluted Average) over 5 years is $32.7 million, with a median of $32.0 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) decreased 14.04% in 2022, then rose 1.62% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $37.7 million in 2021, then fell by 10.68% to $33.7 million in 2022, then fell by 5.43% to $31.8 million in 2023, then increased by 0.54% to $32.0 million in 2024, then decreased by 7.77% to $29.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for MEDP at $29.5 million in Q4 2025, $28.8 million in Q3 2025, and $30.2 million in Q2 2025.